SDF-1 Improves Renal Fibrosis in Type 2 Diabetes Mellitus Involving TGF-β-mediated ECM via PI3K/AKT Signalling

J. XIE, JI ZHANG1 AND H. SHUAI*

Department of Endocrinology, Tongji Hospital, Affiliated to Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, 1Department of Pharmacology, 2Department of Endocrinology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang 441021, Hubei, China

Xie et al.: SDF-1 improves renal fibrosis in DN

The present study investigated the role of stromal cell-derived factor-1 in the progression of renal injury in type 2 diabetic nephropathy. The 8-week old male db/db mice were used as the model of diabetic nephropathy and aged-matched male C57BL/6 mice constituted the control group. Fasting blood glucose, 24 hour urinary albumin and the creatinine clearance rate were measured. The expressions of stromal cell-derived factor-1, CXC chemokine receptor 4 and F4/80 were detected. Normal rat kidney epithelial cells were exposed to stromal cell-derived factor-1α, high glucose, tumour growth factor-β1, valsartan and LY294002, respectively. The extracellular matrix expression was evaluated. It was found that creatinine clearance rate was significantly decreased in 28-week db/db mice compared to the age-matched C57BL/6 mice and valsartan could significantly increase creatinine clearance rate. The expression of stromal cell-derived factor-1, CXC chemokine receptor 4 and F4/80 was significantly increased in the kidney of db/db mice but not in C57BL/6 mice, which was improved with valsartan treatment. In vitro, the expression of CXC chemokine receptor 4 was detected in the rat kidney epithelial cells. Tumour growth factor-β1 increased the expressions of type IV collagen and fibronectin in rat kidney epithelial cells under low glucose and high glucose condition. Stromal cell-derived factor-1α inhibited the harmful effect of tumour growth factor-β1 on extracellular matrix expression, and valsartan exerted synergistic effect on stromal cell-derived factor-1α. Stromal cell-derived factor-1α decreased tumour growth factor-β1 expression and increased p-AKT expression, which were inhibited by LY294002 treatment. Stromal cell-derived factor-1α improved renal fibrosis which might partly involve TGF-β-mediated extracellular matrix via PI3K/AKT pathway.

Key words: Diabetic nephropathy, stromal cell derived factor-1, tumour growth factor-β, PI3K-AKT pathway

Type 2 diabetes mellitus (T2DM) often resulted in microvascular and macrovascular complications, including nephropathy, atherosclerosis, neuropathy and retinopathy. There is increasing evidence that low-level chronic inflammation may in part contribute to the pathogenesis of T2DM and its associated complications[1-2]. Crook et al.[3] proposed that T2DM is an inflammatory state. They found that acute-phase protein levels such as serum sialic acid and IL-6 were elevated in T2DM patients, suggesting that inflammation might be related to the development of T2DM[3,4]. It is well established that inflammatory markers such as TNF-α, IL-6 and C-reactive protein are associated with T2DM and increased risk of T2DM[5,6]. Studies have shown that proinflammatory molecules such as TNF-α and IL-6 cause insulin resistance through activating JNK and IKKβ pathways[7].

There is increasing evidence that low-level chronic inflammation contribute to the pathogenesis of diabetic nephropathy (DN)[8]. Evidence has shown that macrophages and T cells accumulate in the kidney of T2DM[9]. These activated macrophages and leukocytes

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Accepted 21 November 2019
Revised 29 August 2019
Received 17 June 2019
Indian J Pharm Sci 2020;82(1):66-75

*Address for correspondence
E-mail: cnhongxiashuai@163.com
produce various reactive oxygen species, cytokines and proteases. Proinflammatory molecules involved in the progression of DN include chemokines, inflammatory cytokines and adhesion molecules. Renal chronic inflammation is associated with not only promoting glomerular sclerosis and interstitial fibrosis but elevating albuminuria and plasma creatinine[10].

Stromal cell-derived factor-1 (SDF-1), a CXC subfamily chemokine, is a pre-B-cell growth factor[11]. Studies demonstrated that SDF-1 and its receptor, CXCR4, are involved in embryogenesis, migration, progenitor cell homing, survival, proliferation, differentiation and fibrosis[12,13]. Reports showed that SDF-1 binding to the specific receptor CXCR4 participates in the immune and inflammation reaction[14]. Angiotensin II receptor blockers has been shown to reduce the progression of DN[15]. In the present study, the expression of SDF-1/CXCR4 was investigated in the kidney of type 2 diabetic db/db mice and the role of SDF-1 and valsartan on extracellular matrix (ECM) accumulation in normal rat kidney epithelial (NRK) cells. Additionally, it was hypothesized that SDF-1/CXCR4 improved renal fibrosis through transforming growth factor-β TGF-β-PI3K/AKT pathway.

MATERIALS AND METHODS

Male db/db (Leprdb/db) and male C57BL/6 mice (8-w old) were purchased from Shanghai Experimental Animal Centre (Shanghai, China). NRK cell line was purchased from cell centre of Xiangya School of Medicine (Changsha, China). Valsartan was procured from Novartis Pharmaceuticals Company Limited (Beijing, China). AntiCXCR4 antibody for immunohistochemistry was from Abcam. AntiSDF-1 antibody for immunohistochemistry was from BioVision. AntiF4/80 antibody for immunohistochemistry was from Abd-Serotec. SDF-1α and TGF-β1 were purchased from PeproTech. AntiAKT antibody and antiAKT antibody (Ser 473) for western blot were from Santa Cruz. Antitype IV collagen antibody and antifibronectin antibody for western blot were from Shanghai Bio-platform Technology Company (Shanghai, China). Antiβ-actin antibody was from GeneTex.

Animal grouping and treatments:

Ten male db/db mice (8-w old) were used as type 2 diabetic model and ten male C57BL/6 mice (8-w old) served as age-matched control. Valsartan (40 mg/kg/d) was administrated orally by gavage once a day at 3:00 pm. The groups were divided as followed control (C57BL/6 mice); C57BL/6 mice+valsartan; db/db mice; db/db mice+valsartan. The mice were housed in a room maintained at 24±2° and a 12 h light/dark cycle. Mice were allowed free access to mouse chow and sterile water throughout the experimental periods. Body weight and fasting blood glucose (FBG) levels were monitored weekly, while at the beginning and ending of the experiment, fasting blood and 24 h urine were collected. Blood and urine were centrifugated for 5 min (1200 rpm) and were stored at –80°. Twenty weeks later, the mice were sacrificed under light ether anaesthesia, both kidneys were excised from each mouse and embedded in a cryostat to prepare frozen sections. Protein was extracted and stored at –80°. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal use protocol has been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Hubei University of Arts and Science.

Estimation of creatinine and urinary albumin in mice:

FBG was measured using blood glucose teat strips (Onetouch Surestep, Qiangsheng, USA). Creatinine was measured by the alkaline trinitrophenol method. Urinary albumin was evaluated by radioimmunoassay. Creatinine clearance rate (CCr) was calculated as CCr=(UCr×urine volum)/(SCr×body weight), where, UCr represents urine creatinine and SCr represents serum creatinine.

Cell culture and treatment conditions:

NRK cells were cultured in DMEM (25 mM glucose) media containing 100 U/ml penicillin and 100 µg/ml streptomycin supplemented with 10 % foetal calf serum at 37°, under humidified atmosphere of 5 % CO₂ in air. To evaluate the effect of TGF-β on the expression of CXCR4, cells were divided into 2 groups, high glucose medium (25 mM), high glucose medium (25 mM)+TGF-β1 (3×10⁻10 M). Cells were cultured for 3, 6, 12 and 24 h and collected. To evaluate the effect of SDF-1 on the expression of type IV collagen and fibronectin (FN), cells were divided into 10 groups, low glucose medium (5.6 mM), low glucose medium (5.6 mM)+DMSO, low glucose medium (5.6 mM)+TGF-β1 (3×10⁻10 M), low glucose medium (5.6 mM)+TGF-β1 (3×10⁻10 M)+SDF-1α (3×10⁻8 M),low glucosmedium(5.6mM)+TGF-β1(3×10⁻10M)+SDF-1α
(3×10⁻⁹ M)+valsartan (10⁻⁵ M), high glucose medium (25 mM), high glucose medium (25 mM)+DMSO, high glucose medium (25 mM)+TGF-β1 (3×10⁻¹⁰ M), high glucose medium (25 mM)+TGF-β1 (3×10⁻¹⁰ M)+SDF-1α (3×10⁻⁹ M), high glucose medium (25 mM)+TGF-β1 (3×10⁻¹⁰ M)+SDF-1α (3×10⁻⁹ M)+valsartan (10⁻⁵ M).

Cells were pre-treated with TGF-β1 for 3 h. Cells were cultured for 24 h and were collected.

To evaluate the signalling pathway of SDF-1 on renal fibrosis, cells were divided into 10 groups, low glucose medium (5.6 mM); low glucose medium (5.6 mM)+SDF-1α (3×10⁻⁹ M); low glucose medium (5.6 mM)+SDF-1α (3×10⁻⁹ M)+LY294002 (30 μM); low glucose medium (5.6 mM)+LY294002 (30 μM); high glucose medium (25 mM); high glucose medium (25 mM)+SDF-1α (3×10⁻⁹ M); high glucose medium (25 mM)+SDF-1α (3×10⁻⁹ M)+LY294002 (30 μM). Cells were pre-treated with LY294002 for 30 min. Cells were cultured for 24 h and were collected.

**Immunohistochemistry staining of CXR4, SDF-1 and F4/80 in the kidney of mice:**

Freshly isolated kidney specimens were embedded and frozen in the frozen embedding agent and sectioned at 5 μm. The slides were deparaffinized in dimethyl benzene and digested in trypsin. After permeabilized with 0.025 % Triton-X 100 for 10 min at room temperature (RT), the slides were incubated with 3 % H₂O₂ for 10 min at RT. Primary antibodies to macrophage marker F4/80 (1:200), SDF-1 (1:200), or CXCR4 (1:200) were incubated overnight at 4°. Phosphate buffered saline (PBS) was used as the negative control to replace the primary antibodies. After rewarmed to RT for 45 min, the slides were incubated with the appropriate secondary antibodies at RT for 20 min. The sections were incubated with avidin-biotin-peroxidase complex at RT for 20 min. After washed with PBS, the sections were stained with DAB. After stained with hematoxylin, the slides were dehydrated and mounted, observed and photographed under optical microscope. Pro Plus 6.0 image analysis system was used to analyse the expression, and randomly three visual fields were selected under 100 times light microscope per section to calculate average optical.

**Western blot of ECM and AKT pathway in NRK cell:**

Total protein was extracted from cells and concentrations were measured using BCA protein assay kit. Equal amounts of protein were separated by 10 % SDS-PAGE and transferred onto nitrocellulose membranes. Then the membranes were blocked for 1 h with 5 % non-fat dry milk and were incubated with specific primary antibodies of AKT (1:200), p-AKT (1:200), type IV collagen (1:200), Fn (1:200) and β-actin (1:250) overnight at 4°. Horseradish peroxidase-conjugated secondary antibodies (1:1000) were incubated for 1 h at RT. The protein bands were visualized and quantified by enhanced chemiluminescence using an imaging software.

**Real-time PCR of CXCR4 and SDF-1 expression in mouse kidney and ECM expression in NRK cell:**

Total RNA was extracted using Trizol reagent according to the manufacturer’s recommended protocol. The RNA concentration was determined by measuring UV absorbance at 260 nm. Isolated RNA was reverse transcribed into cDNA. Synthesized cDNA was then amplified by real-time PCR using TagMan gene expression assays, with β-actin and GAPDH as internal standards. All PCR were performed in a total volume of 20 μl. Quantitative real-time PCR for =SDF-1α, CXCR4, TGF-β1, FN1 and type IV collagen was performed at 94° for 2 min followed by 45 cycles of denaturing at 94° for 30 s, annealing at 56° for 30 s and extension at 72° for 30 s. Quantitative real-time PCR for rat type IV collagen and rat GAPDH was performed at 94° for 2 min followed by 45 cycles of denaturing at 94° for 30 s, annealing at 57° for 30 s and extension at 72° for 30 s. The PCR primer sequences were shown in Table 1.

**Agarose gel electrophoresis for CXCR4 expression in NRK cell:**

Total RNA was extracted from four group NRK cells using TRizol reagent, respectively. Isolated RNA was reverse transcribed into cDNA. Synthesized cDNA was then amplified by PCR. PCR was performed at 94° for 5 min followed by 35 cycles of denaturing at 94° for 30 s, annealing at 55° for 30 s and extending at 72° for 30 s. After agarose gel electrophoresis (1.5 %), the sample were stained with ethidium bromide and photographed under ultraviolet lamp. The PCR primer sequence of CXCR4, forward primer TAGTGGGCAATGGGTTGGTAATC and reverse primer CTGCTGTAAAGGTTGACGGTGTA. The markers of DNA molecular weight is DL-2000.

**Statistical analyses:**

Data were presented as mean±SD. Statistical analyses
were performed using SPSS Software 13.0 (SPSS, Inc., Chicago, IL, USA). The significance of the differences among the results of clinical characteristic was valued by T-test. ANOVA was used to determine the significance of the differences among the results of western blot, real-time PCR and immunohistochemistry of the groups.

RESULTS AND DISCUSSION

The body weight, FBG and 24 h urinary albumin in 8-w and 28-w old db/db mice were higher compared with those in the same age C57BL/6 mice, respectively (p<0.01). In 28-w old db/db mice, the body weight, FBG and 24 h urinary albumin were higher than those in 8-w old db/db mice (p<0.01). In contrast, 28-w old db/db mice had lower CCr compared to that in age-matched C57BL/6 mice (p<0.01). Valsartan treatment could significantly decrease body weight, 24 h urinary albumin and increased CCr, but had no significant influence on FPG in db/db mice. The effect of valsartan was not found in C57BL/6 mice (Table 2).

Immunohistochemical staining for SDF-1, CXCR4 and F4/80 in the kidney specimens obtained from C57BL/6 mice and db/db mice were performed. In renal glomerulus, tubule and interstitium, sections from db/db mice showed intensive positive granulometric staining for SDF-1, CXCR4 and F4/80 than those in C57BL/6 mice. Valsartan treatment could attenuate the deposition in db/db mice. The effect of valsartan was also not found in C57BL/6 mice (fig. 1 and Table 3).

The mRNA levels of SDF-1 and CXCR4 were evaluated in the kidney of mice (fig. 2). The mRNA levels of SDF-1 and CXCR4 in db/db mice were significantly higher than those in C57BL/6 mice (p<0.01). Valsartan treatment significantly decreased the mRNA level of SDF-1 in db/db mice (p<0.01). Valsartan decreased the expression of CXCR4 mRNA but the difference was not significant. Valsartan treatment had no effect of mRNA levels of SDF-1 and CXCR4 in C57BL/6 mice (fig. 2).

CXCR4 expression in NRK cells was measured by immunohistochemistry and agarose gel electrophoresis. Using immunohistochemistry it was found that the positive granulometric staining for CXCR4 in renal tubule of C57BL/6 mice and db/db mice (figs. 3A, B). Agarose gel electrophoresis showed that CXCR4 mRNA was expressed in renal tubular epithelial cell (fig. 3). Furthermore, TGF-β1 could promote CXCR4 mRNA expression in 3, 6, 12 and 24 h and the peak time was 3 h (fig. 3).

The effect of SDF-1 on ECM (type IV collagen and FN) mRNA and protein expression was explored with different concentrations of glucose in the medium in

### TABLE 1: PRIMERS FOR GENES

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse SDF-1α</td>
<td>CATGCCAGAGCCCACTCAAG</td>
<td>GTCCCTTGCGCTGTGTGCTTAC</td>
</tr>
<tr>
<td>Mouse CXCR4</td>
<td>AGGCCTGTAGACGAAGTGTTG</td>
<td>GGTTCCCTTGAGGTCAGTAC</td>
</tr>
<tr>
<td>Rat SDF-1α</td>
<td>GCACAGGACCAAAGTCACACAT</td>
<td>GGATCCACATTATTCGCGGTCAA</td>
</tr>
<tr>
<td>Rat type IV collagen</td>
<td>GCAGTTGAACAGCCAGAATAC</td>
<td>AGTTACACGCCAGAGGAGA</td>
</tr>
<tr>
<td>Rat TNF</td>
<td>GGACACTATGGGTCAGCTTTGG</td>
<td>TGCTGTTGACACCAGTGAGA</td>
</tr>
<tr>
<td>Rat TGF-B1</td>
<td>GCTGAAACGAGGAGGAGA</td>
<td>CACCTCGAGGTTGGAGTGA</td>
</tr>
<tr>
<td>Mouseβ-actin</td>
<td>TGGTTCCTGTATGGGG</td>
<td>TTTGATGTCGAGCATCAT</td>
</tr>
<tr>
<td>Rat GAPDH</td>
<td>GATGGTGAAGGTCGGT</td>
<td>GAGGTCAATGGGGTCG</td>
</tr>
</tbody>
</table>

### TABLE 2: COMPARISON OF CLINICAL CHARACTERISTICS AMONG DIFFERENT GROUPS

<table>
<thead>
<tr>
<th>Group</th>
<th>Age (w)</th>
<th>Body weight (g)</th>
<th>FBG (mM)</th>
<th>24 h urinary albumin (μg/24 h)</th>
<th>CCr (ml×min×kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C57BL/6</td>
<td>8</td>
<td>20.99±1.58</td>
<td>4.36±0.38</td>
<td>23.76±1.46</td>
<td>0.32±0.06</td>
</tr>
<tr>
<td>28</td>
<td></td>
<td>27.5±2.56</td>
<td>5.48±1.10</td>
<td>25.03±0.85</td>
<td>0.36±0.16</td>
</tr>
<tr>
<td>C57BL/6+valsartan</td>
<td>8</td>
<td>19.38±2.13</td>
<td>5.12±1.74</td>
<td>22.68±2.27</td>
<td>0.37±0.07</td>
</tr>
<tr>
<td>28</td>
<td></td>
<td>25.3±1.76</td>
<td>5.74±0.73</td>
<td>24.86±1.09</td>
<td>0.38±0.07</td>
</tr>
<tr>
<td>db/db</td>
<td>8</td>
<td>36.76±2.98</td>
<td>7.98±1.29</td>
<td>170.43±9.83</td>
<td>1.71±0.44</td>
</tr>
<tr>
<td>28</td>
<td></td>
<td>51.33±1.73</td>
<td>23.87±3.46</td>
<td>259.52±11.24</td>
<td>1.11±0.09</td>
</tr>
<tr>
<td>db/db+valsartan</td>
<td>8</td>
<td>37.65±1.81</td>
<td>8.76±0.56</td>
<td>175.07±11.34</td>
<td>1.49±0.24</td>
</tr>
<tr>
<td>28</td>
<td></td>
<td>47.4±2.79</td>
<td>22.84±3.29</td>
<td>206.00±14.40</td>
<td>1.42±0.12</td>
</tr>
</tbody>
</table>

Comparison of clinical characteristics among groups. The body weight, FBG and 24 h urinary albumin were higher and CCr was lower in db/db mice than those in age matched C57BL/6 mice respectively. Valsartan treatment could significantly decrease body weight, 24 h urinary albumin and increased CCr. *p<0.01 versus the age matched C57BL/6 group and C57BL/6+valsartan group respectively; †p<0.01 versus the 8 w old db/db group
NRK cells. Surprisingly, treated with SDF-1α (3×10^{-9} M) in low (5.6 mM) and high glucose (25 mM) medium, the mRNA and protein levels of type IV collagen and Fn were significantly down-regulated (p<0.01, fig. 4). High glucose (25 mM) significantly induced type IV collagen and FN mRNA and protein expression (p<0.01, fig. 5). Compared to the control, TGF-β significantly increased the mRNA and protein expression of type IV collagen and FN. When the cells were treated with SDF-1α, the increased effect of TGF-β1 on the levels of type IV collagen and FN mRNA was inhibited (p<0.01). Valsartan had synergistic effect on SDF-1α in this effect (p<0.01, fig. 5).

To explore the mechanism of SDF-1 suppressing the ECM expression in NRK, the expression of TGF-β1 was measured. Compared to the control group in low and high glucose medium, SDF-1α treatment significantly down-regulated TGF-β1 mRNA expression (p<0.01, fig. 6A). NRK cells were treated with LY294002 to explore the role of PI3K/AKT pathway in the effects of SDF-1 suppressing TGF-β1 expression. Real-time PCR showed that LY294002 inhibited the suppression of TGF-β1 expression by SDF-1α (p<0.01, fig. 6A). Western blot analysis showed that SDF-1α significantly increased AKT activity and LY294002 had no effect on AKT activity in the absence of SDF-1α.

Abundant evidence has demonstrated that chemokines such as monocyte chemoattractant protein-1 (MCP-1)
are associated with T2DM [16]. Obesity induces macrophage accumulation in adipose tissue and produces many proinflammatory cytokines and chemokines [17]. These cytokines and chemokines could reduce insulin sensitivity via inhibiting insulin receptor signaling and activating intracellular pathways including IKKβ, NF-κB and JNKs to induce insulin resistance [18,19]. Moreover, inflammatory molecules may participate in the pathogenesis of diabetic complication, including DN [20]. Accumulating evidences indicates that chemokines play an important role in renal inflammation and are involved in processes related to DN [21]. Glomerular and interstitial macrophage infiltration has been demonstrated in DN [22]. SDF-1 is a CXC chemokine and its receptor is CXCR4, a seven transmembrane domain G-protein coupled receptor [23].

In our study, the expression of SDF-1 and CXCR4 was explored in the kidney of T2DM and the role of SDF-1 on the renal fibrosis. We used db/db mice as a model of T2DM because db/db mice develop to kidney disease two months after birth with similarities to human DN [24]. Compared with age-matched C57BL/6 mice, 28 w age db/db mice presented increased body weight, FPG and 24 h urinary albumin and decreased CCr. We detected SDF-1 and its receptor CXCR4 exists in the kidney of db/db mice. 28 w db/db mice had intensive depositions of SDF-1, CXCR4 and F4/80 (macrophage/monocyte marker) in renal glomerulus, tubule, interstitial, which was associated with a significantly increase in renal inflammatory levels. Present study showed that valsartan could decrease the expression of SDF-1, CXCR4 and F4/80 infiltration and ameliorate the renal function. The effect of SDF-1 was further investigated on ECM expression in NRK with different concentration glucose medium.

In present study, immunohistochemistry and agarose gel showed that CXCR4 was exist in renal tubular epithelial cell, suggesting that SDF-1 could produce a marked effect through CXCR4 in renal tubular epithelial cell. Furthermore, TGF-β1 could promote CXCR4 mRNA expression in NRK cells. Surprisingly, present study found that SDF-1 suppressed the mRNA and protein levels of type IV collagen and Fn in NRKs both in low (5.6 mM) and high (25 mM) glucose
condition, suggesting the beneficial effect of SDF-1 on renal fibrosis in DN. In addition, it was found that SDF-1 significantly down-regulated the mRNA and protein levels of type IV collagen and FN, respectively. *P<0.01 versus low glucose; †p<0.01 versus high glucose.

**Fig. 4: Effect of SDF-1 on ECM expression in low and high glucose medium in NRK cells**
1. Low glucose 2. low glucose+SDF-1, 3. high glucose, 4. high glucose+SDF-1. SDF-1 significantly down-regulated the mRNA and protein levels of type IV collagen and FN, respectively. *P<0.01 versus low glucose; †p<0.01 versus high glucose.

**Fig. 5: Effect of SDF-1 on TGF-β-induced ECM expression in low and high glucose medium in NRK cells**
1. Low glucose, 2. low glucose+DMSO, 3. low glucose+TGF-β1, 4. low glucose+TGF-β1+SDF-1α, 5. low glucose+TGF-β1+SDF-1α+valsartan, 6. high glucose, 7. high glucose+DMSO, 8. high glucose+TGF-β1, 9. high glucose+TGF-β1+SDF-1α, 10. high glucose+TGF-β1+SDF-1α+valsartan. Compared control, TGF-β significantly increased the mRNA and protein expression of type IV collagen and FN. SDF-1 inhibited the TGF-β-induced mRNA expression in ECM. Valsartan had a synergistic effect of SDF-1. *P<0.01 versus low and high glucose, respectively; **p<0.01 versus low glucose+TGF-β1 and high glucose+TGF-β1 respectively; †p<0.01 versus low glucose+TGF-β1+SDF-1α and high glucose+TGF-β1+SDF-1α.

condition, suggesting the beneficial effect of SDF-1 on renal fibrosis in DN. In addition, it was found that SDF-1 significantly improved TGF-β induced ECM deposition in NRKs. Valsartan orally administered for 20 w in diabetic mice had synergistic effect on SDF-1 in the above effect. Therefore, our observations suggest that SDF-1 could retard the fibrosis progression of DN. This result contrasts to the reports that chemokines promoting renal fibrosis in DN[25,28]. MCP-1 is a specific chemokine that can induce numerous macrophages to infiltrate the glomeruli and renal interstitium. Many studies demonstrated that MCP-1 promoted ECM accumulation to accelerate glomerula sclerosis and tubule interstitial fibrosis[29-31]. Studies revealed that cytokine gene polymorphisms may affect the progression of DN. Gene polymorphism study revealed the risk association between A-2518G polymorphism in the regulatory region of MCP-1 with DN[32]. Studies showed the positive correlation of CCR5 59029G/A with DN[33]. Although some studies have shown that SDF-1/
CXCR4 axis promoted lung fibrosis\cite{34}, SDF-1/CXCR4 signalling was able to promote ECM production in osteoclast\cite{35}. But some studies have shown that SDF-1 could promote ECM degradation to promote tumour migration and invasion\cite{36}. In present study, SDF-1 was found to reduce ECM generation, showing the ability to retard renal fibrosis. Meanwhile, it was also observed that the effect of valsartan on the renal fibrosis. In present study, valsartan orally administered for 20 w decreased 24 h urinary albumin and increased CCr but had no significant influence on FPG. It was also observed that valsartan attenuated the infiltration of macrophage, SDF-1 and CXCR4 into the kidney and decreased type IV collagen and Fn accumulation. Present study suggested the beneficial effects of valsartan on renal damage in DN. These results were coincident with the previous studies\cite{37}. The mechanism underlying protective effect of SDF-1 was further determined on renal fibrosis. TGF-β has been known to promote ECM generation, glomerula sclerosis and tubule interstitial fibrosis\cite{38}. The regulation between TGF-β and other inflammatory mediates is exist. MCP-1 could promote renal fibrosis through inducing TGF-β production\cite{39}. In mesangial cells, TGF-β promotes the progression of renal disease through stimulating MCP-1\cite{40}. TGF-β promotes renal fibrosis through some key signaling pathway, such as Smad2/3, PI3K/AKT, ERK1/2 pathway\cite{41-43}. In present study, it was found that SDF-1 inhibited TGF-β production in NRKs and LY294002 treatment inhibited the effect of SDF-1 suppressing TGF-β expression. A. SDF-1 significantly increased AKT activity and this effect was inhibited by LY294002. *P<0.01 versus control group; **p<0.01 versus SDF-1 group.

Acknowledgements:
This study was supported by Xiangyang Science and Technology Projects ([2012] NO.40) and the National Natural Science Foundation of China (Grant No.81600643).

Conflict of interest:
None.
REFERENCES

7. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
34. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory cytokine-mediated disorder. Nat Rev Immunol 2041;41:1-44.


